TACTICS OF MANAGEMENT OF PATIENTS WITH ATYPICAL ENDOMETRIAL HYPERPLASIA (LITERATURE REVIEW)

Abstract

In the past few years, there has been a gain in the prevalence of hyperplastic processes of the reproductive system in women, among which atypical endometrial hyperplasia (AEH) occupies a special place. Such peculiarities of the clinical manifestation of this disease as the high prevalence, relapsing course, reduced reproductive function and high risk of malignancy reflect the urgency of the problem of prevention and increasing the effectiveness of treatment of endometrial hyperplastic processes. The purpose of the study is to analyze the data presented in modern literature on the tactics of management and treatment of AEH patients. Different tactics of management of AHE patients with effective methods of treating these patients are considered. Hysteroresectoscopy of hyperplastic areas before high-dose progestin therapy has been established to be a safe and highly effective approach to the management and treatment of AEH patients wanted to maintain their fertility. However, organ-preserving treatment must necessarily be accompanied by careful dynamic observation by the gynecologist or oncogynecologist. The optimal method of treating patients in pre- and postmenopausal disease is radical surgical treatment in the amount of extirpation of the uterus with appendages, which should be considered justified for this category of patients.

Keywords

atypical hyperplasia / endometrial cancer / organ preservation treatment / overview

References

[1] Новикова Е.Г., Чулкова О.В., Пронин С.М. Лечение атипической гиперплазии эндометрия. Практическая онкология. 2004; 5 (1): 52-8.

[2] Пушкарев В.А., Кулаковский Е.В., Хуснутдинов Ш.М., Мустафина Г.Т. Атипическая гиперплазия эндометрия (диагностика, клиника и лечение). Креативная хирургия и онкология. 2004; (3): 22-6.

[3] Wang S., Wang Z., Mittal K. Concurrent endometrial intraepithelial carcinoma (EIC) and endometrial hyperplasia. Hum. Pathol. 2015; 2 (1): 1-4

[4] Слюсарева О.А. Доказано или нет? Современные представления о лечении гиперплазии эндометрия. Вестник новых медицинских технологий. 2013; ХX (2): 338-43

[5] Landrum L.M., Zuna R.E., Walker J.L. Endometrial hyperplasia, estrogen therapy, and the prevention of endometrial cancer. In: Di Saia P.J., Creasman W.T., eds. Clinical Gynecologic Oncology. 8ht ed. Elsiver; 2012: 123-9.

[6] Ohyagi-Hara C., Sawada K., Aki I., Mabuchi S., Kobayashi E., Ueda Y. et al. Efficacies and pregnant outcomes of fertility-sparing treatment with medroxyprogesterone acetate for endometrioid adenocarcinoma and complex atypical hyperplasia: our experience and a review of the literature. Arch. Gynecol. Obstet. 2015; 291: 151-7.

[7] Lähteenmäki P., Rauramo I., Backman T. The levonorgestrel intrauterine system in contraception. Steroids. 2000; 65: 693-7.

[8] Ozdegirmenci O., Kayikcioglu F., Bozkurt U., Akgul M.A., Haberal A. Comparison of the efficacy of three progestins in the treatment of simple endometrial hyperplasia without atypia. Arch. Gynecol. Obstet. 2014; 290: 83-6.

[9] Авасова Ч.А., Новикова О.В. Эффективность сочетания бусерелина лонг с внутриматочной левоноргестрел-рилизинг системой в консервативном лечении предрака и начального рака эндометрия. Исследования и практика в медицине. 2017; (2): 16

[10] Chandra V., Kim J., Benbrook D., Dwivedi A., Rai R. Therapeutic options for management of endometrial hyperplasia. J. Gynecol. Oncol. 2016; 27(1): e8

[11] Пашов А.И. Комплексная гормонотерапия агонистами ГнРГ и внутриматочной левоноргестрел-рилизинг системой сложной атипической гиперплазии и аденокарциномы эндометрия: пилотное проспективное наблюдательное исследование. Злокачественные опухоли. 2012; 2 (1): 15-7.

[12] Пронин С.М., Новикова О.В., Андреева Ю.Ю. Применение рилизинг-систем и агонистов гонадотропин-рилизинг-гормона в лечении атипической гиперплазии и начального рака эндометрия. Онкология. Журнал им. П. А. Герцена. 2013; (1): 40-3.

[13] Edris F., Vilos G.A., Al-Mubarak A., Ettler H.C., Hollett-Caines J., Abu-Rafea B. Resectoscopic surgery may be an alternative to hysterectomy in high-risk women with atypical endometrial hyperplasia. J. Minim. Invasive Gynecol. 2007; 14: 68-73.

[14] Giampaolino P., Di Spiezio Sardo A., Mollo A., Raffone A., Travaglino A., Boccellino A. et al. Hysteroscopic endometrial focal resection followed by levonorgestrel intrauterine device insertion as a fertility sparing treatment of atypical endometrial hyperplasia and early endometrial cancer. J. Minim. Invasive Gynecol. 2018. doi: 10.1016/j.jmig.2018.07.001

[15] De Marzi P., Bergamini A., Luchini S., Petrone M., Taccagni G.L., Mangili G., et al. Hysteroscopic resection in fertility-sparing surgery for atypical hyperplasia and endometrial cancer: safety and efficacy. J. Minim. Invasive Gynecol. 2015; 22 (7): 1178-82.

[16] Горных О.А., Табакман Ю.Ю., Биштави А.Х., Гоголадзе Х.Т., Чабров А.М., Костин А.Ю. Результаты хирургического лечения атипической гиперплазии эндометрия. Опухоли женской репродуктивной системы. 2014; (1): 78-80

[17] Byun J.M., Jeong D.H., Kim Y.N., Cho E.B., Cha J.E., Sung M.S. et al. Endometrial cancer arising from atypical complex hyperplasia: The significance in an endometrial biopsy and a diagnostic challenge. Obstet. Gynecol. Sci. 2015; 58(6): 468-74.

[18] Whyte J.S., Gurney E.P., Curtin J.P., Blank S.V. Lymph node dissection in the surgical management of atypical endometrial hyperplasia. Am. J. Obstet. Gynecol. 2010; 202: 176.e1-4.

[19] Taşkın S., Kan Ö., Dai Ö., Taşkın E., Koyuncu K., Alkılıç A. et al. Lymph node dissection in atypical endometrial hyperplasia. Open J. Turkish-German Gynecol. Association. 2017; 18 (3): 127-32.

[20] Qvigstad E., Lieng M. Surgical treatment of endometrial cancer and atypical hyperplasia: a trend shift from laparotomy to laparoscopy. Intern. J. Gynecol. Obstet. 2006; 93(2): 176-81.

[21] Barnett J.C., Judd J.P., Wu J.M., Scales C.D., Myers E.R., Havrilesky L.J. Cost comparison among robotic, laparoscopic, and open hysterectomy for endometrial cancer. Obstet. Gynecol. 2010; 116(3): 685-93.

RIGHTS & PERMISSIONS

Eco-Vector